Should auto stocks be on radar? How to play defence stocks? Amnish Aggarwal explains
ADVERTISEMENT We have seen a range-bound momentum in the Jio Financial stock but on a longer-term picture, there's still conviction on the stock, say experts. What is your view?
Amnish Aggarwal: We do not have any numbers on Jio Financial so far, but having said that, Jio Financials in particular is trying to grow big, as has been the case with some of the other ventures of the Reliance group. Now be it in asset management or segments of financial services, as of now, it is in a very nascent stage because they are handling very limited tangible business as of now. So, it is difficult to say with just one-year, two-year numbers. It will take time for the businesses to shape up. Yes, there could be some need for funding as they expand and that can be raised from the markets given the kind of brand equity the group has.
News flow is coming in for the auto sector. Do you have any take on the automobile space or have you kept the space in your watch list for now?
Amnish Aggarwal: In auto, one needs to be very stock specific because as far as the deal between the European Union, the UK, or the US is concerned, it is not going to impact the entire sector, that is one. Secondly, a lot will depend upon how the India-US deal goes through in terms of exports from many of the Indian companies. As far as the current deal we are going through, it might be beneficial for Tata Motors but not for others.
But the mainstay of the Indian auto companies has been the domestic side where, in two- wheelers, it is Eicher Motors and in case of PVs, M&M is actually doing well. With monsoons being good, there could be some momentum there. It is very difficult to give any single point and very difficult to paint everything with the same brush. But having said that for the consumer or the consumption space, all those factors will play for auto whether it is interest rates, tax cuts, inflation and all that stuff which ideally should be positive for them.But having said that, the groundwork is there but one needs to see how in the coming festival season in particular the auto sales go. But if you go by the current numbers, M&M and Eicher are the two stocks which really continue to look good.
What about oil marketing, oil exploration, and oil producers? At present, ONGC, HPCL, and IOC are showing signs of sharp upsurge. However, oil refiners are tanking down in trade. Any crude related counters, space, sectors on your radar?
Amnish Aggarwal: Due to the benign crude prices, if you look at the oil marketing companies like HPCL, IOC, etc, over the past few months, these stocks have done well and numbers expectations are also built in. So, a lot here will depend on how the crude prices behave. Among oil exploration companies, we have been positive on Oil India in the past.
ADVERTISEMENT But, if the oil prices remain benign, then in some of the refining and the marketing companies, the losses will not come from marketing and those counters can see some stability or an upside from here.
What is your take on the defence sector? Of late, BEL, Mazagon Dock counters have been lagging behind and they have been seeing a bit of a U-turn from higher levels. Is much of the optimism with respect to their order book, and growth trajectory already in the price and any expectation with respect to BEL?
Amnish Aggarwal: Among the defence stocks, particularly after Operation Sindoor, for the next one, one-and-a-half months, there was a very sharp rally in many of these stocks and many of them gave 20-25% return from those levels. Sometimes these stocks go up but the fundamentals take time to catch up. Now, the order books are growing, the growth is there, but the numbers are not going to dramatically change from here. In the long term, these stocks continue to look good whereas in the near term, many of these stocks will move sideways to weak movements and that is a part of what happens naturally with many of the stocks.
ADVERTISEMENT
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
16 minutes ago
- Time of India
Trump calls India's economy 'dead' – but that makes no sense
Recently, Donald Trump, the former U.S. President, made fun of India's economy by calling it 'dead.' But that's a strange and silly thing to say. Think about it: An economy is alive as long as people are buying, selling, and trading things — even if it's just one person giving a teabag to a friend in exchange for some biscuits. That's still trade! India has over 1.4 billion people, which means there are tons of trades and businesses happening every second. So how can it be 'dead'? Also, if India's economy was really dead, why is Trump so eager to sell things like soybeans, corn, and butter to India? You don't trade with something that isn't working. He even spent four months trying to make a trade deal — and only gave up when he got frustrated and added extra taxes (called tariffs) on Indian goods. India's economy is actually growing faster than any other big country's right now. That's not what a dead economy looks like. Even countries that aren't growing fast — like Japan — are still very much alive and running. Trump has said strange things before. Once, he told a man his father would be proud 'looking down on him,' thinking the father had passed away. But the man said his dad was still alive. Trump just replied, 'Then he's even more proud!' So when Trump says 'dead,' it might not mean what you think — or it might not mean anything at all. Facebook Twitter Linkedin Email Disclaimer Views expressed above are the author's own.
Mint
16 minutes ago
- Mint
India unveils first formal rules for drug approval panels in regulatory overhaul
New Delhi: India has issued its first formal playbook for how expert panels should vet new drugs, biologics and medical devices—a move aimed at fixing long-standing concerns about inconsistent and opaque approvals that have delayed critical drug launches and eroded industry trust in the regulatory system. The guidelines, issued by the Central Drugs Standard Control Organization (CDSCO), represent a major overhaul of India's drug approval process and aim to make regulatory decisions faster, more predictable and transparent, according to two government officials and documents reviewed by Mint. The guidelines standardize how Subject Expert Committees (SECs) are formed, how members are selected, and how they must evaluate applications, including the scientific benchmarks and disclosure norms they must follow. The SECs advise the Drugs Controller General of India (DCGI) on whether to clear new drugs, and their decisions have long shaped the trajectory of India's pharmaceutical industry. The CDSCO finalized the guidelines about two weeks ago and circulated them to SEC members for immediate implementation, the officials said. The overhaul follows recommendations from the World Health Organization (WHO), which last year conducted a regulatory review of CDSCO and the office of the DCGI, who heads the organization. The WHO called for stronger transparency and data integrity to align India's system with global standards. India's pharmaceutical industry ranks third globally by volume and 14th by value. It accounts for roughly 20% of the world's generic drug supply and manufactures more than 60,000 products across 60 therapeutic areas. The sector also includes over-the-counter drugs, vaccines, contract manufacturing, biologics and biosimilars. As part of its findings, the WHO urged Indian authorities to implement stronger controls to prevent, detect, and respond to substandard and falsified medical products; to launch a market surveillance program for drug quality monitoring; and to ensure that promotional and advertising claims for medicines are not misleading. These steps are now being implemented by the DCGI and other stakeholders involved in the SEC meetings, according to the officials cited earlier. The SECs play a central role in India's drug approval process, advising the DCGI on whether to approve new drugs, biologics, and medical devices. Each committee includes eight experts—one pharmacologist and seven specialists from research, medical, or regulatory institutions—and requires a four-member quorum to issue recommendations. In the absence of formal guidelines, though, these decisions were often viewed as inconsistent or opaque, delaying product approvals. 'SECs are subject expert committees involved in evaluating approvals of new drugs. Simplification and streamlining the process will help industry in getting drugs approved with predictable speed and more transparency. We appreciate the step taken by DCGI," said Dr. Viranchi Shah, national spokesperson of the Indian Drugs Manufacturers Association (IDMA). Emailed queries to the spokesperson for the health ministry went unanswered at the time of publishing. Clearer mandate, tougher benchmarks According to the guidance document, SEC members must meet strict selection criteria, including a publication record of at least 10 peer-reviewed papers and a citation ratio of 2:1. Experts are appointed for a three-year term and are expected to maintain confidentiality, impartiality, and active participation. Those who fail to attend meetings regularly may be removed. The document specifies that SECs must offer rigorous, science-based evaluations on safety, efficacy, and risk-benefit balance. It outlines the dos and don'ts of deliberations: clinical trial waiver decisions must include clear yes/no recommendations with detailed justifications, and all discussions must remain focused on scientific and regulatory issues, excluding matters such as pricing. 'For new drug and clinical trial applications, the DCGI refers them to the SEC, an expert body that discusses proposals and offers recommendations for approval or rejection. These experts, being external to CDSCO, are not always fully aware of regulatory requirements. This often led to differing, sometimes subjective opinions, a lack of uniformity in decisions, and delays on straightforward matters. Therefore, it's important for the committee to provide uniform decisions, maintain transparency, and offer proper reasoning for approvals and rejections," said one of the two government officials cited earlier, who asked not to be named. The second official added, 'There were persistent discussions during SEC meetings about the absence of a guiding document to regulate or suggest proper functioning. This new guidance note outlines the 'do's and don'ts' for experts. Previously, some companies had even alleged that SEC meetings were not being conducted properly." While officials declined to cite specific past incidents, people familiar with the matter said the lack of consistency and alignment among SEC experts, who advise on key regulatory decisions, had severely affected the functioning of the DCGI in recent years. Industry seeks consistency For years, pharmaceutical companies have raised concerns over the unpredictability of SEC verdicts, especially around clinical trial waivers, which are critical for expediting the launch of generics and biosimilars. The new rules aim to reduce such uncertainty by standardizing decision-making across similar products, unless clear scientific reasons justify a deviation. The document states: 'The SECs are indispensable in the CDSCO's evaluation process due to their specialized expertise, independent perspective and commitment to quality assurance. These committees address complex scientific and regulatory challenges, fostering informed decision-making. By operating transparently and consistently across applications, SECs bolster public trust while safeguarding public health and promoting innovation in the healthcare sector." Public health experts have welcomed the reform. 'Any committee should operate under certain guidance, and it is always beneficial for all members of such a committee to have clarity and a common vision. It's akin to laying down the rules of the game," said Dr. Chandrakant Lahariya, a physician and public health expert. He added: 'The Subject Expert Committee (SEC) is an essential requirement for guiding the drug approvals and other processes in all regulatory bodies. When a new drug is needed, the SEC provides its recommendations to the apex drug regulator. CDSCO is a regulatory organization, and they need guidance from a technical expert committee to make decisions. A regulatory body needs guidance from those who deeply understand the subject."
The Hindu
an hour ago
- The Hindu
Trump welcomes reports India may halt Russian oil imports, calls it a 'good step'
U.S. President Donald Trump on Friday (August 1, 2025) expressed cautious optimism over reports that India may be ending its purchases of Russian oil, calling it a 'good step' while addressing reporters before departing the White House. 'I understand India no longer is going to be buying oil from Russia. That's what I heard. I don't know if that's right or not, but that's a good step,' Mr. Trump said during an impromptu press gaggle on the South Lawn. His remarks come amid growing American scrutiny of India's continued energy and defence ties with Russia, especially in the context of the ongoing war in Ukraine and broader U.S. efforts to isolate the Kremlin economically. While there has been no official confirmation from New Delhi regarding such a move, Mr. Trump's comments mark the first public acknowledgement from the U.S. administration of a potential policy shift by India. Mr. Trump has maintained a firm stance against countries maintaining close commercial ties with Moscow. His administration has already imposed a 25% tariff on Indian imports, citing both trade imbalances and India's longstanding energy relationship with Russia. In his remarks, Mr. Trump did not elaborate on whether the reported change in India's oil policy would impact those tariffs or future negotiations. 'We'll see what happens,' he said. The issue of India's energy imports from Russia has been a point of contention between Washington and New Delhi, with previous administrations urging India to reduce its reliance on Russian crude in the wake of the Ukraine conflict. India has so far defended its purchases as essential for energy security and economic stability. Mr. Trump's tone on Friday, however, suggested an openness to engage with India if the reported shift holds. 'That's a good step,' he repeated, signalling potential diplomatic movement should the reports prove accurate. Officials in New Delhi have historically avoided commenting on energy policy decisions until after implementation. Mr. Trump's brief but pointed remarks come as part of a broader foreign policy strategy to pressure both adversaries and allies into realigning their global partnerships in accordance with US strategic interests. Russia remains under sweeping U.S. sanctions, and energy exports have been a critical lifeline for the Kremlin amid ongoing war-related expenditures. (This article is published in an arrangement with 5WH.)
